dual gip/glp-1 receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Fair Allocation of GLP-1 and

The FDA has issued boxed warnings regarding potential thyroid tumor risk, although human evidence remains inconclusive [4347]

Liraglutide (a daily injection) resulted in a more modest average weight reduction of around 45%, based on 24 trials (9 937 participants), but still increased the proportion of people achieving meaningful weight loss compared with placebo

doi:10.1186/s12876-020-01356-2 47

However, a number of case reports and analysis of adverse effect databases raised the possibility that the drugs increase the incidence of acute pancreatitis

By understanding consumer preferences and drivers of choice, Ankura helps clients adjust strategies to improve revenue and margins accordingly